Stockreport

Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation

Prevail Therapeutics Inc.  (PRVL) 
Last prevail therapeutics inc. earnings: 11/12 09:30 am Check Earnings Report
PDF NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene [Read more]